Resistance to the quinolones almost always arises from the accumulation of mutations in chromosomal genes responsible for the drug targets, permeability, or active efflux. This resistance can be depicted as a stepwise process in which each step, represented by separate mutations, diminishes susceptibility on average 4-to 8-fold. The precise path followed in this stepwise process differs with the quinolone that selects resistance as well as the organism involved. At each step, the influence of each mutation on susceptibility to other quinolones not used in the selection process varies greatly, and a pattern of either cross-resistance or dichotomous resistance may be seen. From an understanding of the stepwise process by which resistance to the quinolones evolves, it is possible to use an 8-fold rule to predict which compounds may provide effective therapy for a given infection and be least likely to select for resistance.
Antimicrobial drug resistance is becoming an increasing cause for concern. As more and more antibiotics are being used in both the inpatient and outpatient setting, more and more resistance is being encountered. It appears that for the first time, antimicrobial drug resistance may be outstripping development of new agents designed to provide effective therapy for infections caused by organisms that are resistant to older agents.
One approach to the design of new effective agents is to understand the mechanisms responsible for resistance to older antibiotics. These mechanisms include alteration in target, production of a drug-inactivating enzyme, and modifications that prevent adequate cellular concentrations of drug from being achieved (table  1 ). An altered target can occur by any one of a variety of mechanisms and is responsible for the penicillin resistance currently seen among pneumococci and the glycopeptide resistance occurring among enterococci [1] [2] [3] [4] . Drug-inactivating enzymes that add a chemical group include the diverse aminoglycoside-inactivating enzymes and chloramphenicol acetyltransferase [5, 6] . The b-lactamases are examples of enzymes that cleave an essential bond to destroy the drug [7, 8] .
"Impermeability" has often been the term applied to the third general mechanism (table 1), but recent work shows this to be a great oversimplification. Resistance via this mechanism not only involves failure of the drug to gain entry into the cell via passive diffusion through the outer membrane of gram-negative bacteria, it also includes failure of the drug to be actively transported across the cytoplasmic membrane-the latter a problem with aminoglycosides. Added to these "impermeability" mechanisms is the recent recognition of active efflux pumps that, when overexpressed, can reduce cellular concentrations of drugs below their effective concentration [9] . Some of these pumps can affect not only compounds in the cytoplasm of the cell, but also those such as b-lactam antibiotics that stay primarily in the periplasmic space of gram-negative bacteria.
Among the 3 general mechanisms of resistance outlined above, 2 appear to be very important to resistance The evolution of resistance to quinolones. Each step in the evolution represents a spontaneous mutation that diminishes quinolone susceptibility 4-to 8-fold. Thus the MIC of the quinolone used to select mutants from the wild type (WT) is 4-to 8-fold diminished for successive first-step (1M), second-step (2M), and third-step (3M) mutants.
to the quinolones: altered target and modifications affecting cellular concentrations of the drugs. It is the purpose of this article to review the mechanisms responsible for resistance to the quinolones and the process whereby organisms develop resistance to the drugs. This process, depending on the quinolones and mechanisms involved, can lead to either cross-resistance or dichotomous resistance to other quinolone agents. An understanding of each is an important first step in determining which quinolones may provide effective therapy for a given infection and be least likely to select for additional resistance to this important drug class.
MECHANISMS OF RESISTANCE TO THE QUINOLONES
Alterations in drug target. Two topoisomerases involved in DNA synthesis, DNA gyrase and topoisomerase IV, have been identified as the major targets of the quinolones [10] [11] [12] . In gram-negative bacteria, DNA gyrase appears to be the favored target, whereas in gram-positive bacteria, topoisomerase IV appears the preferred target. It is thus not surprising that alterations in the subunits of these enzymes are the single most prevalent mechanism of resistance encountered among clinical isolates of both gram-positive and gram-negative bacteria [1, 11, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . Mutations in gyrA, the gene encoding the A subunit of DNA gyrase (GyrA), are the most common mechanism involved in quinolone resistance among gram-negative bacteria, whereas mutations in parC (grlA in staphylococci), the gene encoding the C subunit of topoisomerase IV (ParC), are most commonly encountered among quinolone-resistant grampositive bacteria. Mutations affecting the B subunit of the DNA gyrase (GyrB) and the E subunit of topoisomerase IV (ParE) have also been observed, but these are less commonly encountered and are often found secondary to mutations in the other 2 subunits [1, 11, 12, 27] . Not only are mutations within the genes encoding GyrA and ParC the most common mechanisms responsible for resistance to the quinolones among clinical isolates, but there are "hot spots" for these mutations within similar areas of the genes encoding them [1, 11] . These hot spots are called quinolone resistance-determining regions and involve regions between amino acid 67 and 106 in GyrA, with amino acids 83 and 87 most often involved [1, 11] . Similar quinolone resistancedetermining regions are found in analogous regions of ParC.
Modifications affecting cellular drug concentration. Lowlevel resistance to the quinolones has also been observed in gram-negative bacteria with altered outer membrane porins [27, 28] . This suggests that in these organisms, entrance of the drugs through the outer membrane is retarded and thus inadequate cellular concentrations are achieved. More important are the recent observations that overexpression of active efflux pumps in both gram-positive and gram-negative organisms can lead to quinolone resistance [9, [29] [30] [31] [32] [33] [34] [35] . In gram-positive bacteria, multidrug efflux pumps such as NorA in staphylococci and PmrA in pneumococci are responsible for quinolone resistance [29] [30] [31] [32] 36] .
In gram-negative bacteria, these pumps are more complex and are generally composed of 3 subunits: a transporter protein in the cytoplasmic membrane that removes the drug from the cytoplasm; an outer membrane channel, usually a porin, that funnels the drug out of the cell; and a periplasmic linker protein that connects the other 2 components [9] . This complex arrangement allows for the active efflux of many different drugs, including those that accumulate primarily in the periplasmic space. Resistance to the quinolones and other drugs transported by these efflux pumps arises when those that are constitutively active become more active or when those that are usually inactive become active [9] . The net effect is that efflux increases, significantly reducing cellular accumulation of the drugs. Cross-resistance among the quinolones. The evolution of resistance to quinolone A as selected by quinolone A is shown in the left portion of the figure, with the MIC for each successive mutant (mg/ mL) given below each step. Cross-resistance evolving simultaneously to quinolone B, which is 4-fold more potent than quinolone A against the wild type (WT), is shown (right). With each successive mutation selected by quinolone A, susceptibility to quinolone B diminishes, but differences in potency between the 2 drugs are maintained. If both quinolones achieve a concentration of 2 mg/mL at the site of infection, the 8-fold rule would predict that quinolone B would provide the most effective therapy and be less likely to select for resistance because achievable concentrations exceed the MIC for the wild-type and first-step mutants.
EVOLUTION OF QUINOLONE RESISTANCE
Virtually all quinolone resistance encountered in clinical isolates has involved mechanisms that result from mutations in chromosomal genes of the isolates [1, 11, 27, 28, 37, 38] . There have been rare, often unconfirmed reports of plasmid-mediated resistance to the quinolones (reviewed in Martinez-Martinez et al. [39] ). Although plasmid-mediated resistance is certainly possible both theoretically and scientifically, its rarity precludes its inclusion in any discussion of the evolution of resistance to quinolones at this time. The evolution of resistance to quinolones arises in a stepwise fashion through the accumulation of spontaneous mutations in chromosomal genes encoding cellular products involved with the drugs [1, 11, 27, 28, [40] [41] [42] [43] . These include the drug targets themselves, as well as those cellular mechanisms involved in drug entry into or exit out of the cell. The precise effect of each mutation, taken as a single event, on quinolone susceptibility varies widely depending on the gene involved, the organism, and the specific quinolone. However, in studies involving well-characterized single-step mutants, each mutation affecting the quinolones most often diminished susceptibility 4-to 8-fold [11, 26, 27, 31, 33, [43] [44] [45] [46] [47] . In wild-type cells (i.e., cells with no mutations in their chromosomal genes), the intrinsic susceptibility to a specific quinolone is determined by the ability of the drug to enter and accumulate in the cell and the potency of the drug for the primary target enzyme in the cell-the DNA gyrase or topoisomerase IV.
From these basic principles, the evolution of quinolone resistance can be predicted (figure 1). As wild-type cells replicate, mistakes are made in duplicating the DNA. These mistakes are spontaneous mutations that arise at measurable frequencies usually varying from 1 in 10 6 (mutation Ϫ6 ) to frequency p 10 1 in 10 9 (mutation Ϫ9 ) wild-type cells. Progeny frequency p 10 of wild-type cells with a single mutation affecting quinolone susceptibility are called first-step mutants and are usually 4-to 8-fold less susceptible than wild-type cells to any quinolone affected by the mutation (figure 1). As the first-step mutants replicate, spontaneous mutations can occur among these cells as well. Progeny of first-step mutants with a second mutation affecting quinolone susceptibility are called second-step mutants (figure 1). These are 4-to 8-fold less susceptible than the first-step mutants and 16-to 64-fold less susceptible than the wild-type cells. Single mutations can be accumulated through successive generations to produce third-, fourth-, and fifth-step mutants, and so on ( figure 1 ).
The precise mutation occurring in each step of the pathway varies greatly, depending on the organism involved and the quinolone used to select each mutant [1, 11, 44, [48] [49] [50] . In general, first-step mutants usually involve alterations in the preferred target of the quinolone for the organism. Thus first-step mutants of Streptococcus pneumoniae selected with ciprofloxacin tend to be parC mutants, whereas those selected with sparfloxacin tend to be gyrA mutants, reflecting the different preferred target of these 2 quinolones for this species [11, 50] . Furthermore, firststep mutants of gram-negative bacteria tend to have altered gyrA, whereas first-step mutants of gram-positive bacteria tend to have altered parC. Precisely where in the stepwise evolution mutations affecting permeability and efflux occur is highly variable [15, 31, 36] . However, among Staphylococcus aureus, first-step mutants may be efflux mutants [36] .
The evolution of clinically relevant resistance (i.e., MIC above the susceptible breakpoint) to any specific quinolone is determined by the intrinsic potency of the drug against the wild type, Figure 3 . Dichotomous resistance among the quinolones. The evolution of resistance to quinolone A as selected by quinolone A is shown (left), with each successive mutation causing diminished susceptibility to quinolone A. Because the mechanisms responsible for the mutations in the first-step (1M) and third-step (3M) mutants do not affect susceptibility to quinolone B, a pattern of dichotomous resistance emerges. Only the mutation in the second-step (2M) mutant reduces susceptibility to quinolone B. WT, wild type.
the achievable levels of drug at the site of infection, and the number of successive mutations required before the diminished susceptibility produced by each mutation exceeds the achievable levels of drug. The greater the intrinsic potency of the drug and the higher the achievable levels, the greater the number of mutations required for a clinically relevant level of resistance to be achieved. For example, with ciprofloxacin, it was not surprising to see resistance emerging quickly among staphylococci, because these organisms possessed only marginal susceptibility to the drug initially (table 2) . Thus, a single mutation in grlA was often sufficient to confer resistance to ciprofloxacin. Such was not the case for Escherichia coli, which showed a much greater intrinsic susceptibility to ciprofloxacin (table 2) . In this organism, multiple mutations involving drug target and drug accumulation were required for resistance to occur.
This predictable, stepwise evolution of resistance to the quinolones has a positive side in that it provides an additional basis on which to predict which quinolone may provide effective therapy for a given infection and have a lower chance of selecting resistance. If a quinolone is desired for therapy, the MIC of the quinolone for the organism causing the infection should be multiplied by 8. The resultant product is the likely MIC of the next-step mutant that will arise spontaneously from the strain. Because the number of cells in an active infection readily exceeds 10 9 , it is likely that in addition to the parental cells, there are already a few mutant cells present at the site of the infection. Thus, the preferred quinolone to treat the infection would be one that achieves a concentration at least 8-fold above the MIC of the infecting strain at the site of infection. This concentration provides adequate coverage not only for the parental cells of the infecting strain but also is likely to cover the next-step mutant as well.
For example, if the MIC of a particular quinolone is 1 mg/mL against a bacterial strain, the MIC of the drug for the next-step mutant is likely to be 4-8 mg/mL. Applying the 8-fold rule, if concentrations of the quinolone at the site of infection do not exceed 8 mg/mL, another quinolone should be chosen for therapy. Obviously, the higher the achievable concentration over the MIC of the infecting strain, the greater the number of successive mutants that will be covered by the therapy, making selection of resistance highly unlikely. Once this rule of 8 has been invoked, additional factors that may affect the selection of therapy should, of course, be taken into consideration, as always.
Drlica [12] has taken a somewhat different approach to this same general principle. He suggests that, for each quinolone, the mutant prevention concentration (MPC) should be determined. The MPC is that concentration that prevents the growth of the next-step mutant of a bacterial strain. It is determined by plating ∼10 10 cells into varying concentrations of the quinolone and determining the concentration at which no growth occurs [12] . This is certainly a valuable approach for categorizing quinolones and their relative ability to prevent selection of mutants, and this strategy should be pursued during the investigation of any quinolone. However, because it involves tests that are not performed routinely by hospital laboratories, the MPC is unlikely to be available to a physician when he or she is determining which quinolone is best for the patient. Because an MIC is often available, the 8-fold rule can be applied readily in the clinical setting. Were a study to be performed to determine the MPC and the MIC derived from the 8-fold rule, it is likely that results would be comparable because both concentrations reflect the amount of quinolone required to prevent growth of the next-step mutant.
Cross-resistance and dichotomous resistance. Many of the earlier fluoroquinolones were affected similarly by mutations that diminished susceptibility to the quinolones. Thus when one compared the potency of the various quinolones among organisms resistant to 1 drug, a pattern of cross-resistance was often seen (figure 2). Cross-resistance implies that as organisms become less susceptible to one drug in a class, they become less susceptible to others in the class. Thus, a quinolone that was 4-fold more potent than another against wild-type cells would continue to be 4-fold more potent against each successive mutant, but each mutant would be less susceptible to both drugs. If the achievable concentrations of both drugs were 2 mg/mL, as shown in figure 2 , the more potent drug would be preferable for therapy because it would cover both wild-type and first-step mutants. However, because of the cross-resistance pattern of the mutants, neither drug would provide adequate coverage for any successive mutants. Cross-resistance between ciprofloxacin and ofloxacin is illustrated in the data shown for wild types and first-step mutants in table 2.
With the development of newer fluoroquinolones, especially those with an 8-methoxy group such as moxifloxacin, a different pattern of resistance among quinolones became apparent. It is now clear that not all quinolones are equally affected by all mutations involved in resistance [1, 17, 19, 20, 26, 36, 44, NOTE. MIC must differ at least 4-fold from parental strain for cross-resistance. Clin, clinafloxacin; cpfx, ciprofloxacin; moxi, moxifloxacin; nfx, norfloxacin; ofx, ofloxacin; spfx, sparfloxacin; tofx, tosufloxacin; VPH, Vibrio parahaemolyticus.
a The numbers 1, 2, 3, and 4 refer to first-step mutant, second-step mutant, third-step mutant, and fourth-step mutant. b The precise location of mutation is indicated by gene, if known. If phenotypic tests were used to ascertain the mutation, the result listed as a presumptive mechanism. Mutations of parental mutant used to select successive mutant are indicated by gene only. The type of resistance relative to the drug used to select the mutant is indicated in parentheses by C if cross-resistant and by D if dichotomous resistant. c Unknown. Genetic lesion was not found among the genes investigated in the study. [48] [49] [50] [51] [52] . For example, differences in primary targets are responsible for resistance affecting one quinolone but not another. As mentioned above, in S. pneumoniae, the primary target for ciprofloxacin is topoisomerase IV, whereas the primary target for sparfloxacin is DNA gyrase. Thus, single-step mutants selected by sparfloxacin that are altered in gyrA will be less susceptible to sparfloxacin but not to ciprofloxacin. Conversely, those mutants selected with ciprofloxacin that are altered in parC will be less susceptible to ciprofloxacin but not to sparfloxacin. Differences in quinolone hydrophobicity also influence the effect of specific efflux pumps on quinolone resistance [9, 31, 48, [52] [53] [54] . In staphylococci, NorA has a greater effect on susceptibility to norfloxacin and ciprofloxacin than it has on susceptibility to sparfloxacin, gatifloxacin, clinafloxacin, grepafloxacin, and moxifloxacin.
Because not all mechanisms of resistance affect all quinolones equally, a pattern of dichotomous resistance has emerged, especially between older and newer quinolones in studies with gram-positive bacteria (figure 3). With dichotomous resistance, the pattern of evolving resistance to 2 quinolones resembles that of a branching tree, with the path of one drug leaving the other at each mutation step that affects only 1 of the 2. In the example shown, the evolution of resistance to quinolone A as selected by quinolone A is shown, with each successive mutation reducing susceptibility 4-to 8-fold. However, simultaneous evolution of resistance to quinolone B does not follow the same path because mutations occurring in the first-and third-step mutants do not affect quinolone B.
Examples of dichotomous resistance and cross-resistance among quinolones are shown in table 3 for mutants isolated sequentially in vitro from wild-type strains. The different pathways to resistance depending on the drug used in selection of the mutants are illustrated in the data shown in table 3 from Pan and Fisher [49] . Examples of dichotomous resistance and cross-resistance for clinical isolates found to be quinolone resistant are shown in table 4 .
Selection of resistance. It may be argued that because of the dichotomous resistance between older and newer fluoroquinolones, the latter should be held in reserve for use with infections caused by gram-positive strains resistant to the older agents. However, it should be noted that the newer fluoroquinolones, in addition to being less affected by mechanisms causing resistance to older agents, are less likely to select resistant mutants (i.e., the mutation frequencies for first-step mutants selected by the newer quinolones are lower than those for mutants selected by the older drugs) [12, 44, 47, 48] . Thus the likelihood of a spontaneous mutation occurring that affects the newer quinolones is much smaller. This has been hypothesized to be due to the greater lethal effect of the newer quinolones [12] . Although the precise mechanism or mechanisms responsible for the lethal effect of the quinolones is unknown, induction of the SOS response appears to be involved [11, 12] . The more rapid the lethal effect, the less likely cells containing mutations arising from an activated SOS system are to arise. The smaller likelihood of selection of resistance by newer quinolones may also be related to the fact that some appear to target both DNA gyrase and topoisomerase IV equally [49] . In S. pneumoniae, clinafloxacin appears to target both DNA gyrase and topoisomerase IV. Thus, for significant resistance to clinafloxacin to appear in this organism, mutations in genes encoding both targets need to occur.
Along these same lines, if resistance to newer quinolones among gram-positive organisms requires 2 mutations, and firststep mutants are less likely to be selected by them, older agents should definitely be avoided. Use of older agents would be more likely to select first-step mutants. Many of these mutants, although appearing fully susceptible to newer agents, have a silent mutation that will be expressed when a second mutation occurs. If in this scenario a newer quinolone is introduced, the nextstep mutant to be selected is a second-step mutant. Studies have shown that mutation frequencies for second-step mutants selected by newer quinolones are similar to those selected by older agents [12, 48] . Thus resistance to the newer quinolones will arise sooner in this scenario because the strains have been primed for resistance by use of older agents than if the newer agents had been used from the start. This possibility is illustrated by results obtained in studies performed by Fukuda et al. [48] , shown in table 3. First-step mutants of S. aureus MS 5935 selected by older quinolones showed dichotomous resistance to sparfloxacin and were altered in grlA. Second-step mutants altered in both grlA and gyrA were 256-fold less susceptible to sparfloxacin than the wild-type or first-step mutant. This greatly exceeds the 8-fold decrease in susceptibility seen with single mutations and suggests that the grlA mutation was silent until the second mutation affecting gyrA occurred. When the second mutation occurred, both contributed significantly to the greatly reduced susceptibility to sparfloxacin. These results, coupled with the observations that sparfloxacin-resistant clinical isolates of staphylococci usually possess mutations in both grlA and gyrA [16, 17] , strongly suggest that a mutation in both targets is necessary for resistance to occur.
CONCLUSIONS
The mechanisms responsible for resistance to the quinolones are many and varied. As more quinolones are developed, the mechanisms responsible for resistance promise to become more numerous and complex. However, as the evolution of resistance becomes better understood and the mechanisms responsible for cross-resistance and dichotomous resistance become elucidated, it should be possible to predict which quinolones are more likely to provide effective therapy and which are less likely to select for resistance to this important drug class.
